Brolucizumab
Sign in to saveAlso known as RTH258, ESBA1008
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Wikidata facts
- Subclass of
- chemical compound
Show 2 more facts
- World Health Organisation international non-proprietary name
- brolucizumab
- subject has role
- monoclonal antibody
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- History
- Society and culture
- Safety concerns
- Names
- Research
- References
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye).
Excerpted from Wikipedia’s “Brolucizumab” article, available under the CC BY-SA 4.0 licence.